Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Axonics, Inc. AXNX
$54.26
-$0.79 (-1.46%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
2783951344.00000000
-
week52high
79.92
-
week52low
40.98
-
Revenue
273702000
-
P/E TTM
-55
-
Beta
0.38666600
-
EPS
-1.13000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 июл 2023 г. в 10:59
Описание компании
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Overweight | Overweight | 02 авг 2022 г. |
| Truist Securities | Buy | Buy | 02 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 02 авг 2022 г. |
| Morgan Stanley | Overweight | Overweight | 02 авг 2022 г. |
| Truist Securities | Buy | Buy | 20 июл 2022 г. |
| Piper Sandler | Overweight | Overweight | 05 окт 2022 г. |
| RBC Capital | Outperform | 21 окт 2022 г. | |
| Truist Securities | Buy | Buy | 17 окт 2022 г. |
| Jefferies | Hold | 12 окт 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 11 окт 2022 г. |
| Needham | Hold | Buy | 10 окт 2022 г. |
| Wells Fargo | Overweight | Overweight | 01 ноя 2022 г. |
| Truist Securities | Buy | Buy | 01 ноя 2022 г. |
| Morgan Stanley | Overweight | Overweight | 06 янв 2023 г. |
| Truist Securities | Buy | Buy | 20 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Ford Alfred J Jr | D | 53998 | 541 | 01 февр 2023 г. |
| Sama Rinda | D | 75783 | 4334 | 01 февр 2023 г. |
| Sama Rinda | D | 80117 | 741 | 01 февр 2023 г. |
| Woock John | D | 65302 | 3398 | 01 февр 2023 г. |
| Woock John | D | 68700 | 581 | 01 февр 2023 г. |
| Noblett Karen | D | 42215 | 795 | 01 февр 2023 г. |
| Noblett Karen | D | 43010 | 136 | 01 февр 2023 г. |
| COHEN RAYMOND W | D | 160596 | 6932 | 01 февр 2023 г. |
| COHEN RAYMOND W | D | 167528 | 1185 | 01 февр 2023 г. |
| Dearen Danny L. | D | 23993 | 2772 | 01 февр 2023 г. |
Новостная лента
Axonics, Inc. (AXNX) Q1 2023 Earnings Call Transcript
Seeking Alpha
01 мая 2023 г. в 21:36
Axonics, Inc. (NASDAQ:AXNX ) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call Participants Chris Pasquale - Nephron Research Richard Newitter - Truist Securities Nathan Treyback - Wells Fargo Adam Maeder - Piper Sandler Michael Polark - Wolfe Research Shagun Singh - RBC Capital Markets Mike Matson - Needham and Company Anthony Petrone - Mizuho Securities Michael Sarcone - Jefferies Operator Thank you for standing by and welcome to the Axonics' First Quarter 2023 Results Conference Call. At this time, all participants are in listen-only mode.
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
01 мая 2023 г. в 19:01
Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.
Axonics to Report First Quarter 2023 Financial Results on May 1
Business Wire
10 апр 2023 г. в 06:00
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report first quarter 2023 financial results after the close of trading on Monday, May 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results.
Axonics, Inc. (AXNX) Q4 2022 Earnings Call Transcript
Seeking Alpha
01 мар 2023 г. в 22:59
Axonics, Inc. (NASDAQ:AXNX ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call Participants Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Chris Pasquale - Nephron Research Cecilia Furlong - Morgan Stanley David Rescott - Truist Adam Maeder - Piper Sandler Michael Polark - Wolfe Research Shagun Singh - RBC Capital Markets Michael Sarcone - Jefferies Mike Matson - Needham and Company Operator Good day and thank you for standing by. Welcome to Axonics' Fourth Quarter 2022 Results Conference Call.
Axonics Modulation Technologies (AXNX) Surpasses Q4 Earnings and Revenue Estimates
Zacks Investment Research
01 мар 2023 г. в 18:48
Axonics (AXNX) delivered earnings and revenue surprises of 104.35% and 0.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?